• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细胞色素P450 17α-羟化酶/17,20-裂解酶(CYP17A1)基因T-34C多态性与子宫内膜癌风险无关。

CYP17A1 T-34C polymorphism is not associated with endometrial cancer risk.

作者信息

Yang Xueying, Feng Aihua, Liu Fengying, Li Qun, Zhang Jing, Yang Chuanhua, An Yujun

机构信息

Department of Gynaecology and Obstetrics, The Fourth People's Hospital of Jinan, Jinan, 250000, China.

出版信息

Tumour Biol. 2013 Oct;34(5):2583-7. doi: 10.1007/s13277-013-0805-0. Epub 2013 Apr 23.

DOI:10.1007/s13277-013-0805-0
PMID:23609033
Abstract

The association between CYP17A1 T-34C polymorphism and endometrial cancer risk has been inconsistent and underpowered. To clarify the effect of CYP17A1 T-34C polymorphism on the risk of endometrial cancer, a meta-analysis of all available studies relating CYP17A1 T-34C polymorphism to the risk of endometrial cancer was conducted. The authors searched PubMed, EMBASE, Scopus, and VisionCite databases updated on March 2013. Data were extracted by two independent authors and pooled odds ratio (OR) with 95 % confidence interval (CI) was calculated. Finally, seven studies with 1,570 endometrial cancer cases and 2,474 controls were included in the meta-analysis. There was no statistically significant association between CYP17A1 T-34C polymorphism and endometrial cancer under heterogeneous codominant model (OR = 0.91, 95 %CI = 0.68-1.21). Although CYP17A1 T-34C polymorphism was marginally associated with endometrial cancer risk under homogeneous codominant model (OR = 0.69, 95 %CI = 0.49-0.99), the significant association was not stable after sensitivity analysis. We concluded that CYP17A1 T-34C polymorphism might not be one risk factor in the carcinogenesis of endometrial cancer. Further large and well-designed studies are needed to confirm this association.

摘要

细胞色素P450 17α-羟化酶1(CYP17A1)基因T-34C多态性与子宫内膜癌风险之间的关联一直存在争议且研究力度不足。为了阐明CYP17A1基因T-34C多态性对子宫内膜癌风险的影响,我们对所有将CYP17A1基因T-34C多态性与子宫内膜癌风险相关的现有研究进行了荟萃分析。作者检索了2013年3月更新的PubMed、EMBASE、Scopus和VisionCite数据库。由两位独立作者提取数据,并计算合并比值比(OR)及95%置信区间(CI)。最终,七项研究共纳入1570例子宫内膜癌病例和2474例对照,纳入荟萃分析。在异质性共显性模型下,CYP17A1基因T-34C多态性与子宫内膜癌之间无统计学显著关联(OR = 0.91,95%CI = 0.68 - 1.21)。虽然在同质性共显性模型下,CYP17A1基因T-34C多态性与子宫内膜癌风险存在边缘性关联(OR = 0.69,95%CI = 0.49 - 0.99),但敏感性分析后该显著关联并不稳定。我们得出结论,CYP17A1基因T-34C多态性可能不是子宫内膜癌发生的危险因素之一。需要进一步开展大规模、设计良好的研究来证实这种关联。

相似文献

1
CYP17A1 T-34C polymorphism is not associated with endometrial cancer risk.细胞色素P450 17α-羟化酶/17,20-裂解酶(CYP17A1)基因T-34C多态性与子宫内膜癌风险无关。
Tumour Biol. 2013 Oct;34(5):2583-7. doi: 10.1007/s13277-013-0805-0. Epub 2013 Apr 23.
2
No association between CYP17 T-34C polymorphism and breast cancer risk: a meta-analysis involving 58,814 subjects.CYP17 T-34C 多态性与乳腺癌风险之间无关联:一项涉及 58814 例受试者的荟萃分析。
Breast Cancer Res Treat. 2010 Jul;122(1):221-7. doi: 10.1007/s10549-009-0679-4. Epub 2009 Dec 15.
3
Variants in hormone biosynthesis genes and risk of endometrial cancer.激素生物合成基因变异与子宫内膜癌风险
Cancer Causes Control. 2008 Nov;19(9):955-63. doi: 10.1007/s10552-008-9160-7. Epub 2008 Apr 25.
4
The relationship between the polymorphisms of the CYP17A1 gene and hypertension: A meta-analysis.CYP17A1基因多态性与高血压的关系:一项荟萃分析。
J Renin Angiotensin Aldosterone Syst. 2015 Dec;16(4):1314-20. doi: 10.1177/1470320315585683. Epub 2015 May 18.
5
[A case-control study on genetic polymorphism of CYP17 MspA(1)I and its association with endometrial cancer risk].CYP17 MspA(1)I基因多态性及其与子宫内膜癌风险关联的病例对照研究
Zhonghua Zhong Liu Za Zhi. 2007 Apr;29(4):266-9.
6
Genetic variation in CYP17A1 and pancreatic cancer in a population-based case-control study in the San Francisco Bay Area, California.加利福尼亚州旧金山湾区基于人群的病例对照研究中 CYP17A1 的遗传变异与胰腺癌。
Int J Cancer. 2010 Feb 1;126(3):790-5. doi: 10.1002/ijc.24792.
7
Association between cytochrome P450 1A1 MspI polymorphism and endometrial cancer risk: a meta-analysis.细胞色素P450 1A1 MspI基因多态性与子宫内膜癌风险的关联:一项荟萃分析。
Tumour Biol. 2013 Oct;34(5):2545-50. doi: 10.1007/s13277-013-0798-8. Epub 2013 Aug 7.
8
Prostate cancer with variants in CYP17 and UGT2B17 genes: a meta-analysis.具有CYP17和UGT2B17基因变异的前列腺癌:一项荟萃分析。
Protein Pept Lett. 2012 Jan;19(1):62-9. doi: 10.2174/092986612798472848.
9
Meta-analysis of an association of codon 72 polymorphisms of the p53 gene with increased endometrial cancer risk.p53基因密码子72多态性与子宫内膜癌风险增加相关性的Meta分析。
Genet Mol Res. 2011 Oct 31;10(4):3609-19. doi: 10.4238/2011.October.31.11.
10
Genetic variation in CYP17 and endometrial cancer risk.细胞色素P450 17α-羟化酶/17,20-裂解酶基因变异与子宫内膜癌风险
Hum Genet. 2008 Mar;123(2):155-62. doi: 10.1007/s00439-007-0454-8. Epub 2008 Jan 3.

引用本文的文献

1
Association of Endogenous Pregnenolone, Progesterone, and Related Metabolites with Risk of Endometrial and Ovarian Cancers in Postmenopausal Women: The BFIT Cohort.绝经后妇女内源性孕烯醇酮、孕酮和相关代谢物与子宫内膜癌和卵巢癌风险的关联:BFIT 队列。
Cancer Epidemiol Biomarkers Prev. 2021 Nov;30(11):2030-2037. doi: 10.1158/1055-9965.EPI-21-0669. Epub 2021 Aug 31.
2
CYP17 polymorphism (rs743572) is associated with increased risk of gallbladder cancer in tobacco users.细胞色素P450 17α-羟化酶/17,20-裂解酶多态性(rs743572)与吸烟人群患胆囊癌风险增加有关。
Tumour Biol. 2014 Jul;35(7):6531-7. doi: 10.1007/s13277-014-1876-2. Epub 2014 Apr 1.

本文引用的文献

1
CYP17 gene polymorphisms and prostate cancer risk: a meta-analysis based on 38 independent studies.CYP17 基因多态性与前列腺癌风险:基于 38 项独立研究的荟萃分析。
Prostate. 2011 Aug 1;71(11):1167-77. doi: 10.1002/pros.21332. Epub 2011 Jan 12.
2
Cytochrome P450 17 (CYP17) is involved in endometrial cancinogenesis through apoptosis and invasion pathways.细胞色素 P450 17(CYP17)通过凋亡和侵袭途径参与子宫内膜癌的发生。
Mol Carcinog. 2011 Jan;50(1):16-23. doi: 10.1002/mc.20680.
3
Lack of association between CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis of 22,090 cases and 28,498 controls.
CYP17 MspA1 多态性与乳腺癌风险之间缺乏关联:22090 例病例和 28498 例对照的荟萃分析。
Breast Cancer Res Treat. 2010 Jul;122(1):259-65. doi: 10.1007/s10549-009-0695-4. Epub 2009 Dec 24.
4
CYP17 inhibition as a hormonal strategy for prostate cancer.CYP17抑制作为前列腺癌的一种激素治疗策略。
Nat Clin Pract Urol. 2008 Nov;5(11):610-20. doi: 10.1038/ncpuro1237.
5
Variants in hormone biosynthesis genes and risk of endometrial cancer.激素生物合成基因变异与子宫内膜癌风险
Cancer Causes Control. 2008 Nov;19(9):955-63. doi: 10.1007/s10552-008-9160-7. Epub 2008 Apr 25.
6
CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility.细胞色素P450 1A1(CYP1A1)、磺基转移酶1A1(SULT1A1)和磺基转移酶1E1(SULT1E1)基因多态性是子宫内膜癌易感性的危险因素。
Cancer. 2008 May 1;112(9):1964-73. doi: 10.1002/cncr.23392.
7
Genetic variation in CYP17 and endometrial cancer risk.细胞色素P450 17α-羟化酶/17,20-裂解酶基因变异与子宫内膜癌风险
Hum Genet. 2008 Mar;123(2):155-62. doi: 10.1007/s00439-007-0454-8. Epub 2008 Jan 3.
8
Cancer screening in the United States, 2007: a review of current guidelines, practices, and prospects.2007年美国的癌症筛查:当前指南、实践与前景综述
CA Cancer J Clin. 2007 Mar-Apr;57(2):90-104. doi: 10.3322/canjclin.57.2.90.
9
The T/C polymorphism of the CYP17 gene and G/A polymorphism of the CYP19 gene in endometrial cancer.子宫内膜癌中CYP17基因的T/C多态性与CYP19基因的G/A多态性
J Exp Clin Cancer Res. 2006 Sep;25(3):411-6.
10
The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis.细胞色素P450酶在内源信号通路和环境致癌作用中的作用。
Nat Rev Cancer. 2006 Dec;6(12):947-60. doi: 10.1038/nrc2015.